Compare 3M Company (MMM) vs Novo Nordisk A/S (NVO) Price & Performance

3M CompanyTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

3M Company vs Novo Nordisk A/S — how do they compare? 3M Company trades at $170.76 (market cap $82.99B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 2.7× 3M Company's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.

	MMM	NVO
Market Cap	$82.99B	$220.53B
Sector	Industrials	Health
52-Week High	$174.61	$71.70
52-Week Low	$141.10	$35.29
Enterprise Value	$91.39B	$239.49B
Dividend Yield	1.96%	3.63%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MMM

3M beats Q2 earnings and raises outlook, driven by growth in optics and industrial segments.Seeking Alpha · 4 hours agoBullish 3M shares jump 10% after beating Q2 earnings and raising full-year EPS forecastGordon Thompson · 6 hours agoBullish 3M shares jump 9% after Q2 earnings beat and raised 2026 guidanceProactive Investors · 11 hours agoBullish View details →

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 9 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 13 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.